Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,579.22
(
-0.03%
)
US TECH 100
23,426.40
(
-0.40%
)
Dow Jones
46,278.64
(
0.15%
)
Brent Oil
99.52
(
2.82%
)
Bitcoin
69,948.00
(
-1.34%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 165246

Monday, 08/12/2013 8:54:42 PM

Monday, August 12, 2013 8:54:42 PM

Post# of 257275
GSK/(ViiV) Tivacay—The average sales projection of six analysts polled by Reuters is $900M in 2017 (or sooner):

http://in.reuters.com/article/2013/08/12/us-glaxosmithkline-hivdrug-idINBRE97B0WU20130812

In order for that sales level to be attained, GSK will have to promote the use of Tivacay with Truvada rather than with GSK’s own Epzicom.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today